Allows consistent and objective interpretations, verified by a pathologist, for each patient

Produces a semi-quantitative score

Reduces inter- and intra-observer variability in the interpretation of IHC stains

The most advanced, clinically validated pathology solutions
Ventana is the only company in the industry to offer a comprehensive portfolio. Our full breast panel includes HER2 (4B5), ER (SP1), PR (1E2), Ki-67 (30-9) and p53 (DO-7) image analysis algorithms for use along with their accompanying VENTANA IHC assays.*

All IHC breast markers in the VENTANA portfolio have both image analysis and digital read application FDA 510(k) clearances. There are two intended uses obtained with the 510(k) clearance:

Clinical use of the software algorithm to semi-quantify the biomarker

Digital read, or clearance to manually read and score the biomarker using a computer monitor in lieu of a microscope. This means a pathologist is able to digitally view a slide on a computer monitor, assign a score, and then sign out the case with a diagnosis or opinion, with or without the assistance of an image analysis algorithm.

Related Links

VENTANA

Empowering | Innovation

This may be a regulated product; it may not be available in all geographies. Please consult your local representative for availability and restrictions. This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.